Wednesday, 25 April 2018

MS@thelimits 2018

Do you want to attend the MS@thelimits 2018 meeting?  This year the focus is on cellular therapies, comorbidities and trials in more advanced MS. 

Have a look at the programme. 

Following on the success of last year's MS at the limits meeting in London we are holding a second meeting this November. 

The feedback we got from last year's meeting was exceptionally good and I think it was due to the quality of the speakers and the format; i.e. 20-minute talk and 20-minute discussion. 

If you want to attend please register online.



  1. Treatment cessation?

    Background: Several disease-modifying drugs (DMD) are available for the treatment of MS, and most patients with relapsing-remitting disease are currently treated. Data on when and how DMD treatment can be safely discontinued are scarce. Methods: Fifteen MS patients, treated with natalizumab for >5 years without clinical and radiological signs of inflammatory disease activity, suspended treatment and were monitored with MRI examinations and clinical follow-up to determine recurrence of disease activity. This group was compared with a retrospectively analysed cohort comprising 55 MS patients treated with first-line DMDs discontinuing therapy in the time period of 1998-2015 after an analogous stable course. Results: Natalizumab discontinuers were followed for on average 19 months, and follow-up data for 56 months were available for first-line DMD quitters. Two-thirds of natalizumab treated patients experienced recurrent inflammatory disease activity, and one third had recurrence of rebound character. In contrast, 35% of first-line DMD quitters had mild recurrent disease activity, and no one exhibited rebound. Conclusions: Withdrawal of a first-line DMD after prolonged treatment in middle-aged MS patients with stable disease appears to be relatively safe, while natalizumab withdrawal in a similar group of patients cannot be safely done without starting alternative therapy.

    Discontinuation of disease modifying treatments in middle.... Available from: [accessed Apr 26 2018].

    Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab


  2. "Have a look at the programme."

    Love to look at it..unfortunately it is pretty illegible
    due to the low file resolution.
    It's o.k.. you guys are still learning this internet stuff.

    1. Click on the slide share icon, then click view full screen.
      Job done! ;-)

  3. This sounds great. Can you clarify is this is primarily for researchers/clinicians to get together and work things out, or to inform MSers, or both? As someone with MS I've a vested interest and like to follow the science, but don't want to attend if its a typical conference where specialists talk to each other and let contents fly over the heads of the rest of the audience. Thanks

  4. profG may answer, but last time it was full of MS professionals and the debate may fly over your head, sometimes it flies over my head.


Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.